Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.
Latest From Pricing Debate
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.
Obamacare repeal has been replaced by rebrand as Trump administration plans to use ACA’s Medicare demonstration powers to send discount cards to seniors, one of a slew of health care announcements that include Rx importation, pre-existing conditions, insulin and EpiPens.
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.